B+
Bull case
25%
Probability
Target price
$65.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
RIGL
RigelANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Existing-product growth and profitable Q2 operations could support the launch investment while VEPPANU adds a new oncology revenue stream and R289 provides clinical optionality. [#SEC-8K-2026-08-04]
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-02.
What can break
2026 revenue outlook excludes VEPPANU product sales, limiting visibility into the new launch. [#SEC-8K-2026-08-04]
Momentum
91
Value
68
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $53.00 · Bull $65.00 · Bear $34.00Analysis 2026-10-25; returns require an exact persisted reference.
Earnings
2026-11-02
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $63.00
Why
Momentum91 · Δ7d +2.9
Value68 · Δ7d -0.5
Sentiment61 · Δ7d -6.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-02.
- • Value remains the lead driver in the composite, 7D delta -0.5.
Contradictions & invalidation
- • 2026 revenue outlook excludes VEPPANU product sales, limiting visibility into the new launch. [#SEC-8K-2026-08-04]
- • R289 dose selection and preliminary data could be delayed or clinically disappointing. [#SEC-8K-2026-08-04]
- • VEPPANU uptake or reimbursement may disappoint, and R289 data or timing may fail to support further development.
Catalyst clock
2026-11-02
VEPPANU prescription uptake
Lead driver: Value · See fundamentals
Momentum
91
8% active weight
Current posture
7d trendImproving
Δ7d
+2.9
Δ21d
-1.0
Value
68
47% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-1.3
Sentiment
61
45% active weight
Current posture
7d trendSoftening
Δ7d
-6.4
Δ21d
-12.6
Why this grade
Composite grade A. Momentum 90.9 / Value 67.6 / Sentiment 60.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$53.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$944.27M
Beta
1.11
Shares Out
18.68M
P/E (TTM)
6.7
P/S (TTM)
2.65
P/FCF (TTM)
10.97
Rev YoY
-22.6%
EPS YoY
-73.1%
Gross Margin
+91.4%
Op Margin
+31.5%
Net Debt
-$101.65M
Current Ratio
1.94
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data